Abbott’s vascular business exemplifies our constant pursuit of providing best-value solutions to a growing global health challenge. Today, cardiovascular diseases are the leading cause of death in Europe, affecting the lives of millions of people.1 Our commitment to put value at the heart of healthcare means providing the most accurate, least invasive and most complementary diagnostic, treatment and aftercare options. It is important that we provide patients with effective and safe solutions that at the same time support physicians in taking the best choices for treatment and aftercare.
Along with diagnostic and imaging devices, market-leading stents2, catheters, guidewires and vessel closure devices, we optimise outcomes for patients at all stages and enhance the physician’s user experience like never before. Our products and solutions reflect the high quality and safety of care, combined with optimal outcomes for patients and long-term efficiency.
That’s our value-proposition.
Our introducers are designed to provide reliable vascular access and reduce trauma for the benefit of the patient. Available in a range of configurations and lengths, our introducers are designed to fit any procedural need of physicians.
Abbott’s focus on the entire interventional procedure, combined with state-of-the-art manufacturing technology and rigorous testing, help ensure we deliver on our promise to provide the best possible product.
In torque control, Abbott’s guidewire provides confident access to a variety of coronary artery lesions, even the most complex ones. It is intended to facilitate the placement of balloon dilatation catheters during percutaneous transluminal angioplasty (PTA), or stenting procedures, and supports the physiological analysis and assessment of blood flow by means of Fractional Flow Reserve (FFR) diagnosis, improving the physician’s control and patient outcomes.
The guidewire provides confident, trackable access to target lesions and to distinguish the vasculature. To stay ahead of trends and address challenges, our strong in-house development focus and patent-protected technology ensures our guidewires are cutting edge.
A pioneer in closure technologies, Abbott Vascular offers suture-mediated and clip-based vessel-closure products designed to facilitate secure closure of the vascular access sites from 5 to 24 French after coronary and peripheral catheterisations. Our technologies offer a mechanical closure that allows physicians to close, challenge and confirm on the table the security of the close by delivering a non-masking percutaneous repair. Abbott’s solutions promote primary-intention healing with less scarring.3 Primary-intention healing occurs where vessel wall edges are brought together, adjacent to each other. This can be achieved with suture, stitches, staples and clips.
A physiological analysis of the blood flow assesses the severity of artery blockages. This can be done with the measurement of FFR which is an advanced tool that supports physicians in making the best treatment decisions for their patients. By measuring pressure in the coronary arteries, it provides a detailed, physiological analysis of blood flow blockages in the heart, compared to common X-ray examinations of the blood vessels.
Clinical trials confirm that FFR reduces the risk for heart attacks and death for 2 years4 and decreases the risk of unplanned hospitalisation for urgent revascularisations5, preventing unnecessary hospital costs.14, 16
OCT offers superior image resolution, accurate lumen measurements and imaging speed compared with other imaging technologies.6,7 It produces diagnostic images of the coronary vessels, with automated measurements in real time and enhances the physician’s decision-making before, during and after percutaneous coronary intervention (PCI).8 Evidence from several recent randomised controlled trials support the use of OCT-guided PCI as a safe and efficient alternative to angiography-guided PCI8,9,10, resulting in the reduction of unnecessary hospital expenses.
Effective lesion preparation and optimal stent deployment are critical to successful patient outcomes. Complex lesions require a balloon catheter specifically designed for challenging and complex anatomy. The unique design features of Abbott’s solutions provide physicians with excellent balloon conformability, ultra-low crossing profiles and outstanding push transmission. Our balloon dilatation catheters are the perfect tool to optimise vessel preparation and stent placement even for complex lesions.
Our market-leading2 stents help opening blocked arteries through minimally-invasive interventions. To date, over 11.6 million of our drug-eluting stents (DES) have been implanted worldwide.2 They are designed to provide unparalleled safety and superior performance due to their unique design. Several trials, involving more than 100.000 patients, confirmed that our DES lead to low stent thrombosis rates, even when dual antiplatelet therapy was interrupted11, and at most challenging lesions, in patients at all disease stages.12, 13, 15 As a global market leader, our stents stand for unrivalled quality and safety, reducing complications for patients and enhancing physician’s treatment options.
At Abbott, we’re advancing integrated imaging, diagnostic and treatment platforms for vascular disease. We provide products and solutions that reflect increased quality and safety of care along the patient pathway, providing hospitals with an opportunity to save unnecessary costs from the short- to long-term. To support ongoing operations at your hospital, we provide capability-building and maintenance services at our training facilities and distribution centres in Europe.
And we’re working on next-generation breakthroughs that unlock the potential to improve the way doctors take care of people with vascular diseases. Want to learn more about our solutions and our commitment to value-based procurement? Access our resource centre or visit leading events on vascular disease treatment and procurement around Europe.
1. Wilkins E, Wilson L, Wickramasinghe K, Bhatnagar P, Leal J, Luengo-Fernandez R, Burns R, Rayner M, Townsend N(2017). European Cardiovascular Disease Statistics 2017. European Heart Network, Brussels.
2. Numbers are based on data of DES implants through Q1 2017. Comparative claim based on unit usage in U.S., Japan, China, India, top 5 Western Europe, and Korea. Other leading DES: BSX stents (Promus Element, Promus Element Plus, Promus Premier, Synergy); MDT stents (Resolute, Resolute Integrity, Resolute Onyx); Terumo stents (Nobori, Ultimaster); Biotronik stent (Orsiro); and Biosensors stent (BioMatrix). Data on file at Abbott Vascular.
3. Danks, Roy R. Would Closure Technique. Medscape. WebMD, 17 May 2016. Web. 20 July 2017.
4. Pijls, N.J. et al. (2010). Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-Year Follow-Up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) Study. Journal of the American College of Cardiology, 56(3), 177-184. doi: 10.1016/j.jacc.2010.04.012
5. De Bruyne, B. et al. FAME 2 Trial Investigators. (2012). Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. New England Journal of Medicine, 367(11), 991-1001. doi: 10.1056/NEJMoa1205361 3. Fearon, W. F., et al. (2010). Economic evaluation of fractional flow reserve-guided percutaneous coronary intervention in patients with multivessel disease. Circulation, 122(24), 2545-2550.
6. Regar, E, et al. Optical coherence tomography for evaluation of coronary stents in vivo. Expert Rev Cardiovasc Ther. 2013;11:577–588.
7. Prati F, Di Vito L, Bionid-Zoccai G, et al. Angiography alone versus angiography plus optical coherence tomography to guide decision-making during percutaneous coronary intervention: the Centro per la Lotta contro l'Infarto-Optimisation of Percutaneous Coronary Intervention (CLI-OPCI) study. EuroIntervention. 2012;8:823-9.
8. Ziad A, et al. (2016): Optical coherence tomography compared with intravascular ultrasound and with angiography to guide coronary stent implantation (ILUMIEN III: OPTIMIZE PCI): a randomised controlled trial. Lancet 2016; 388: 2618–28
9. Belle L, et al. (2016). Optical Coherence Tomography to Optimize Results of Percutaneous Coronary Intervention with Non-ST-Elevation Acute Coronary Syndrome: Results of the Multicenter, randomized DOCTORS study. American Heart Association
10. Waksman R, Optical Frequency Domain Imaging vs. IVUS in PCI: The OPINION Trial- One-Year Primary Endpoint Results. Presented at EuroPCR 2016, May 16-19, 2016, Paris, France.
11. Généreux P, Stent Thrombosis and Dual Antiplatelet Therapy Interruption with Everolimus-Eluting Stents - Insights from the Xience V Coronary Stent Systems Trials. Circ Cardiovasc Interv. 2015;8:e001362.
12. Moreno R, et al. A Randomised Comparison Between Everolimus- and Sirolimus-Eluting Stents in Chronic Coronary Total Occlusions. Final Results of the CIBELES Trial. Presented at EuroPCR 2012.
13. Tandjung K. Comparison of Frequency of Periprocedural Myocardial Infarction in Patients with and without Diabetes Mellitus to Those with previously unknown but elevated Glycated Hemoglobin Levels (from the TWENTE Trial). Am J Cardiol 2012;110:1561–1567
14. Fearon FW, et al. 3 Year Clinical Outcome and Cost-Effectiveness of FFR-Guided PCI in Stable Patients with Coronary Artery Disease: FAME II Trial. Presented at TCT 2017.
15. Teeuwen K, et al. Randomized Multi-center Trial Investigating the Angiographic Outcome of Hybrid Sirolimuseluting Stents with Biodegradable Polymer Against Everolimus-eluting Stents with Durable Polymer in Chronic Total Occlusions (PRISON IV), JACC: Cardiovascular Interventions (2016), doi: 10.1016/j.jcin.2016.10.017.
16. Omerovic E, “FFR Guided Complete Revascularization during Primary Angioplasty is cost‐effective – Effects on Social Costs”. Presented on May 16, 2017 at EuroPCR 2017.
You are now leaving www.valueatheart.com. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.
For health care professionals in EUROPE excepted those practicing in France as the following pages are intended to all International health care professionals and are not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Other health care professionals should select their country in the top right corner of the website.
Please note that the following pages are exclusively reserved for health care professionals in countries with applicable health authority product registrations. To the extent this site contains information, reference guides and databases intended for use by licensed medical professionals, such materials are not intended to offer professional medical advice. Prior to use, please consult device labelling for prescriptive information and operating instructions.
This Website is protected by the laws on copyright and by the relevant international conventions. It is strictly forbidden to make copies, whether partial or total and on whichever media without prior approval.